Clofarabine

Therapy-Related Myeloid Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

9 Active assets in the Therapy-Related Myeloid Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Fludarabine National Cancer Institute (NCI)	Phase 2	B
Nivolumab M.D. Anderson Cancer Center	Phase 2	B
Busulfanum M.D. Anderson Cancer Center	Phase 2	B
Rituximab M.D. Anderson Cancer Center	Phase 2	B
Cyclophosphamide M.D. Anderson Cancer Center	Phase 2	B

View all 14 →

Same molecule, other indications

Clofarabine is also rated in:

acute myeloid leukemia with 11q23 abnormalitiesActive

BB

Indicative · Phase 3

70 / 100

acute myeloid leukemia, del(5q31-q32)Dormant

BB

Indicative · Phase 3

70 / 100

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BB

Indicative · Phase 3

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.